135 related articles for article (PubMed ID: 9365042)
1. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma.
Shiota G; Kishimoto Y; Suyama A; Okubo M; Katayama S; Harada K; Ishida M; Hori K; Suou T; Kawasaki H
J Hepatol; 1997 Oct; 27(4):661-8. PubMed ID: 9365042
[TBL] [Abstract][Full Text] [Related]
2. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.
Atta MM; el-Masry SA; Abdel-Hameed M; Baiomy HA; Ramadan NE
Clin Biochem; 2008 Oct; 41(14-15):1131-9. PubMed ID: 18616935
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
4. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma.
Tangkijvanich P; Janchai A; Charuruks N; Kullavanijaya P; Theamboonlers A; Hirsch P; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Dec; 18(4):237-43. PubMed ID: 11316045
[TBL] [Abstract][Full Text] [Related]
6. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
7. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between serum anti-P53 and familial clustering of hepatocellular carcinoma in Guangxi].
Pang Y; Li GJ; Wu JZ; Wu JL; Chen WQ; Ning QY; Wei YH; Hu DF; Qin L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):206-9. PubMed ID: 22487835
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
10. Serum P53 Abs in HCC patients with viral hepatitis - type C.
EI-Emshaty HM; Gadelhak SA; Abdelaziz MM; Abbas AT; Gadelhak NA
Hepatogastroenterology; 2014 Sep; 61(134):1688-95. PubMed ID: 25436364
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma.
Raedle J; Oremek G; Truschnowitsch M; Lorenz M; Roth WK; Caspary WF; Zeuzem S
Eur J Cancer; 1998 Jul; 34(8):1198-203. PubMed ID: 9849479
[TBL] [Abstract][Full Text] [Related]
12. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
13. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
[TBL] [Abstract][Full Text] [Related]
14. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.
Qin LX; Tang ZY; Ma ZC; Wu ZQ; Zhou XD; Ye QH; Ji Y; Huang LW; Jia HL; Sun HC; Wang L
World J Gastroenterol; 2002 Jun; 8(3):459-63. PubMed ID: 12046070
[TBL] [Abstract][Full Text] [Related]
15. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
16. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.
Volkmann M; Müller M; Hofmann WJ; Meyer M; Hagelstein J; Räth U; Kommerell B; Zentgraf H; Galle PR
Hepatology; 1993 Sep; 18(3):559-65. PubMed ID: 7689531
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma.
Aoki T; Miyamoto A; Marubashi S; Nagano H; Umeshita K; Fujiwara Y; Dono K; Nakamori S; Sakon M; Monden M
Int J Oncol; 2004 Feb; 24(2):441-6. PubMed ID: 14719122
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.
Hayashi H; Sugio K; Matsumata T; Adachi E; Takenaka K; Sugimachi K
Hepatology; 1995 Dec; 22(6):1702-7. PubMed ID: 7489977
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma.
Akere A; Otegbayo JA
Singapore Med J; 2007 Jan; 48(1):41-4. PubMed ID: 17245515
[TBL] [Abstract][Full Text] [Related]
20. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.
Liu J; Ma Q; Zhang M; Wang X; Zhang D; Li W; Wang F; Wu E
Eur J Cancer; 2012 Oct; 48(15):2328-38. PubMed ID: 22459764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
